ORCID Profile
0000-0002-6239-8494
Current Organisations
National Cancer Institute
,
Johns Hopkins University
,
University of Agriculture Faisalabad
,
Earle A Chiles Research Institute
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: American Association for Cancer Research (AACR)
Date: 03-04-2023
DOI: 10.1158/1940-6207.22534390.V1
Abstract: Supplementary Figure from Aspirin and the Risk of Colorectal Cancer According to Genetic Susceptibility among Older In iduals
Publisher: American Association for Cancer Research (AACR)
Date: 29-03-2022
DOI: 10.1158/1940-6207.CAPR-22-0011
Abstract: There is strong evidence to support prophylactic aspirin use for the prevention of colorectal cancer. However recent recommendations suggest the risk of bleeding in older in iduals outweighs the benefit. We sought to determine whether some older in iduals might still benefit from aspirin based on their genetic susceptibility.
Publisher: Springer Science and Business Media LLC
Date: 19-09-2017
DOI: 10.1038/S41467-017-00608-2
Abstract: Immune checkpoint blockers (ICB) have become pivotal therapies in the clinical armamentarium against metastatic melanoma (MMel). Given the frequency of immune related adverse events and increasing use of ICB, predictors of response to CTLA-4 and/or PD-1 blockade represent unmet clinical needs. Using a systems biology-based approach to an assessment of 779 paired blood and tumor markers in 37 stage III MMel patients, we analyzed association between blood immune parameters and the functional immune reactivity of tumor-infiltrating cells after ex vivo exposure to ICB. Based on this assay, we retrospectively observed, in eight cohorts enrolling 190 MMel patients treated with ipilimumab, that PD-L1 expression on peripheral T cells was prognostic on overall and progression-free survival. Moreover, detectable CD137 on circulating CD8 + T cells was associated with the disease-free status of resected stage III MMel patients after adjuvant ipilimumab + nivolumab (but not nivolumab alone). These biomarkers should be validated in prospective trials in MMel.
Publisher: American Association for Cancer Research (AACR)
Date: 11-02-2022
Publisher: American Association for Cancer Research (AACR)
Date: 03-04-2023
DOI: 10.1158/1940-6207.22534390
Abstract: Supplementary Figure from Aspirin and the Risk of Colorectal Cancer According to Genetic Susceptibility among Older In iduals
Publisher: American Association for Cancer Research (AACR)
Date: 03-04-2023
DOI: 10.1158/1940-6207.C.6547486.V1
Abstract: Abstract Although aspirin has been considered a promising agent for prevention of colorectal cancer, recent data suggest a lack of benefit among older in iduals. Whether some in iduals with higher risk of colorectal cancer may benefit from aspirin remains unknown. We used a 95-variant colorectal cancer polygenic risk score (PRS) to explore the association between genetic susceptibility to colorectal cancer and aspirin use in a prospective study of 12,609 in iduals of European descent ages ≥70 years, enrolled in the ASPirin in Reducing Events in the Elderly (ASPREE) double-blinded, placebo-controlled randomized trial (randomized controlled trial RCT). Cox proportional hazards models were used to assess the association of aspirin use on colorectal cancer, as well as the interaction between the PRS and aspirin treatment on colorectal cancer. Over a median of 4.7 years follow-up, 143 participants were diagnosed with incident colorectal cancer. Aspirin assignment was not associated with incidence of colorectal cancer overall [HR = 0.94 95% confidence interval (CI), 0.68–1.30] or within strata of PRS ( i P /i for interaction = 0.97). However, the PRS was associated with an increased risk of colorectal cancer (HR = 1.28 per SD 95% CI, 1.09–1.51). In iduals in the top quintile of the PRS distribution had an 85% higher risk compared with in iduals in the bottom quintile (HR = 1.85 95% CI, 1.08–3.15). In a prospective RCT of older in iduals, a PRS is associated with incident colorectal cancer risk, but aspirin use was not associated with a reduction of incident colorectal cancer, regardless of baseline genetic risk. Prevention Relevance: There is strong evidence to support prophylactic aspirin use for the prevention of colorectal cancer. However recent recommendations suggest the risk of bleeding in older in iduals outweighs the benefit. We sought to determine whether some older in iduals might still benefit from aspirin based on their genetic susceptibility. /
No related grants have been discovered for Asad .Umar.